Pizotifen (BC 105) in migraine prophylaxis.
Pizotifen, an antaminic, was investigated in a double-blind placebo controlled trial to evaluate its efficacy in migraine prophylaxis. It was found to be and effective prophylactic in a proportion of migraine patients, reducing the frequency as well as the severity of headaches. Some patients showed weight gain. Several patients have continued treatment for up to 2 years with good control of their migraine and a reduction in the amount of medicament required for the acute attack.
D001007:Anxiety; D001835:Body Weight / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D003863:Depression / Q000139:chemically induced; D006429:Hemiplegia / Q000139:chemically induced; D006801:Humans; D008881:Migraine Disorders / Q000517:prevention & control*; D010918:Pizotyline / Q000008:administration & dosage* / Q000009:adverse effects; D013876:Thiophenes / Q000008:administration & dosage*
D013876:Thiophenes; D010918:Pizotyline